Table 2 ROBIS assessments
Review | Phase 2 | Phase 3 | |||
|---|---|---|---|---|---|
1. Study eligibility criteria | 2. Identification and selection of studies | 3. Data collection and study appraisal | 4. Synthesis and findings | Risk of bias in the review | |
2023_Bellaver | Low risk | Low risk | Low risk | Low risk | Low risk |
2022_Yang Zi | Low risk | Low risk | Low risk | Low risk | Low risk |
2020_Shao | Low risk | Low risk | Low risk | Low risk | Low risk |
2020_Medrinal | Low risk | Unclear risk | Low risk | Low risk | Low risk |
2020_Tarazan | Unclear risk | Low risk | Unclear risk | Low risk | Low risk |
2020_Wei | Unclear risk | Unclear risk | Low risk | Low risk | Low risk |
2020_Yang3 | Low risk | Low risk | Low risk | Low risk | Low risk |
2018_Yang2 | Unclear risk | Unclear risk | Low risk | Low risk | Low risk |
2018_Yang1 | Unclear risk | Low risk | Low risk | Low risk | Low risk |
2018_Sanchéz-Solana | Unclear risk | Low risk | Unclear risk | Unclear risk | Unclear risk |
2018_Lambell | Low risk | Low risk | Low risk | Low risk | Low risk |
2017_Annoni | Low risk | Low risk | Low risk | Low risk | Low risk |
2017_McKittrick | Low risk | Unclear risk | Unclear risk | High risk | High risk |
2016_Price | Low risk | Low risk | Low risk | Low risk | Low risk |
2012_Ydemann | Unclear risk | Unclear risk | High risk | High risk | High risk |
2010_Prentice | Low risk | Low risk | Unclear risk | Unclear risk | Unclear risk |
2006_Hohl | High risk | Unclear risk | Unclear risk | Unclear risk | Unclear risk |
1998_De Jonghe | Low risk | Unclear risk | Unclear risk | Unclear risk | Unclear risk |